–FDA lifted clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia
–Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022
–LogicBio to present at ASGCT 2022 Annual Meeting
https://www.biospace.com/article/releases/logicbio-therapeutics-reports-first-quarter-2022-financial-results-and-highlights-recent-business-updates/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.